Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) to Post FY2028 Earnings of $16.10 Per Share, Roth Capital Forecasts

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) – Equities research analysts at Roth Capital issued their FY2028 EPS estimates for shares of Cyclacel Pharmaceuticals in a report released on Thursday, May 2nd. Roth Capital analyst J. Aschoff expects that the biotechnology company will post earnings per share of $16.10 for the year. The consensus estimate for Cyclacel Pharmaceuticals’ current full-year earnings is ($18.70) per share.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($6.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.35) by $0.12. The business had revenue of $0.03 million during the quarter.

A number of other brokerages have also commented on CYCC. Roth Mkm dropped their price objective on shares of Cyclacel Pharmaceuticals from $21.00 to $11.00 and set a “buy” rating on the stock in a report on Friday. StockNews.com assumed coverage on Cyclacel Pharmaceuticals in a research report on Thursday, May 2nd. They set a “hold” rating for the company.

Cyclacel Pharmaceuticals Stock Performance

Shares of CYCC stock opened at $2.07 on Monday. Cyclacel Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $13.20. The company’s 50 day moving average price is $2.18 and its two-hundred day moving average price is $3.47. The company has a market capitalization of $2.73 million, a P/E ratio of -0.08 and a beta of 0.54.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.